Bringing Medicines for HIV Prevention to a Family Planning Clinic

NCT ID: NCT06930508

Last Updated: 2025-04-16

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 83 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-07-01
• Study Completion Date: 2026-06-30

Brief Summary

The goal of this clinical trial is to understand what patients and physicians think about providing medications to prevent HIV transmission to patients in a family planning clinic. These medications are known as pre-exposure prophylaxis, or PrEP. The main questions to answer are:

1. Do patients find it acceptable to be asked about, and offered, PrEP during their visit to a family planning clinic?

2. What things make it easier or harder to ask about PrEP in a family planning clinic setting?

3. What things make it easier or harder to begin PrEP in a family planning clinic setting?

Patient participants:

1. Will receive standardized counseling about PrEP.

2. Will have the opportunity to begin PrEP as part of their routine, ongoing care.

3. Will be asked to complete a survey about their experiences.

Physician participants:

1. Will receive standardized education about PrEP.

2. Will talk to patient participants about PrEP, and support patient participants who want to begin PrEP.

3. Will be asked to complete pre-and post-study surveys about their experiences.

4. May be asked to complete a post-study in-depth interview about their experiences.

Detailed Description

In the proposed pilot study, the investigators' goal is to improve community health resources available to Rhode Islanders to lower their risk of HIV acquisition, via the following specific aims:

1. Evaluate the patient acceptability of HIV pre-exposure prophylaxis (PrEP) eligibility screening and initiation in an ob/gyn-staffed family planning clinic.

2. Assess the barriers, facilitators, and feasibility of PrEP eligibility screening in an ob/gyn-staffed family planning clinic.

3. Assess the barriers, facilitators, and feasibility of delivery and uptake of PrEP in an ob/gyn-staffed family planning clinic.

Overall, the investigators' expected outcome is to have exploratory data to inform a scalable intervention to implement PrEP access, which can be deployed in family planning clinic settings, and which is designed in accordance with acceptability and feasibility data from patients and providers. Since the existing data suggest that ob/gyn-staffed family planning clinics are an ideal site both as a catchment area for patients who are at higher risk for HIV acquisition, and in terms of technical capacity and provider skill set, the next step to expand PrEP service delivery in these settings is to assess the barriers and facilitators to such care, in order to meet patients where they are, with the care they need. The goal is to situate the protocol to fit into the usual clinical workflow of a busy family planning clinic.

The investigators will develop and implement a standardized PrEP eligibility screening instrument and initiation protocol, based on CDC guidelines. The investigators will survey patient and physician participants about feasibility and acceptability of study procedures. Patient participants will be approached by a research assistant, who will inform eligible individuals about the purpose, risks, and benefits of the study. The research assistant will obtain informed consent from participants. Physicians will then screen participants for PrEP eligibility per protocol, and will offer initiation of PrEP. These medications are not investigational, are part of standard of care STI prevention, and are not themselves the primary subject of this study.

The investigators' primary data collection will be via survey. Patient participants will receive a $25 gift card for completing the post-intervention survey. Physician participants will receive pre- and post-study surveys, and a subgroup will participate in focused interviews.

There is no control arm in this study. The alternative to participation in this study is to simply undergo (or provide) routine care in the investigators' Family Planning Clinic, which does not currently include PrEP provision - though, as described above, such care is within the scope of routine care in ob/gyn settings.

Conditions

HIV; PrEP

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SCREENING
• Blinding Strategy: NONE

Study Groups

Patient Participant

Group Type: EXPERIMENTAL

Patient participant screening

Intervention Type: BEHAVIORAL

Patient participants will be provided with the standardized PrEP screening and initiation protocol.

Physician Participant

Group Type: EXPERIMENTAL

Physician participant training

Intervention Type: BEHAVIORAL

Physician participants will be trained in the investigators' standardized PrEP screening and initiation protocol.

Interventions

Patient participant screening

Patient participants will be provided with the standardized PrEP screening and initiation protocol.

Intervention Type: BEHAVIORAL

Physician participant training

Physician participants will be trained in the investigators' standardized PrEP screening and initiation protocol.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

This study will include patient participants who:

• Are age 16 or older
• Are presenting for care at the Women and Infants Hospital of Rhode Island Family Planning Clinic
• Speak English or Spanish
• Have decisional capacity

This study will exclude patient participants who:

• Are currently seeking abortion care

This study will include physician participants who:

• Provide care at the Women and Infants Hospital of Rhode Island Family Planning Clinic

This study will not have any specific exclusion criteria for physician participants.

• Minimum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Advance RI CTR

UNKNOWN

Sponsor Role: collaborator

Women and Infants Hospital of Rhode Island

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Women and Infants Hospital of Rhode Island

Providence, Rhode Island, United States

Countries

United States

Central Contacts

Benjamin P Brown, MD, MS

Role: CONTACT

benjamin_brown@brown.edu

401-274-1122 ext. 41501

Erica J Hardy, MD, MMSc, MA

Role: CONTACT

erica_hardy@brown.edu

401-453-7950

Facility Contacts

Benjamin P Brown, MD, MS

Role: primary

benjamin_brown@brown.edu

401-274-1122 ext. 41501

Erica J Hardy, MD, MMSc, MA

Role: backup

erica_hardy@brown.edu

401-453-7950

Other Identifiers

2282543-1

Identifier Type: -

Identifier Source: org_study_id